142 related articles for article (PubMed ID: 11121650)
1. The definition of biochemical failure in patients treated with definitive radiotherapy.
Kattan MW; Fearn PA; Leibel S; Potters L
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1469-74. PubMed ID: 11121650
[TBL] [Abstract][Full Text] [Related]
2. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.
Thames H; Kuban D; Levy L; Horwitz EM; Kupelian P; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):929-43. PubMed ID: 14575823
[TBL] [Abstract][Full Text] [Related]
3. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. American Society for Therapeutic Radiology and Oncology.
Hanlon AL; Hanks GE
Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):559-66. PubMed ID: 10701734
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.
Stock RG; Klein TJ; Cesaretti JA; Stone NN
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):753-8. PubMed ID: 19084351
[TBL] [Abstract][Full Text] [Related]
5. The impact of irregularly rising prostate-specific antigen and "impending failure" on the apparent outcome of localized prostate cancer following radiotherapy.
Hodgson DC; Catton CN; Warde P; Gospodarowicz MK; Milosevic MF; McLean M B M; Catton P
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):957-63. PubMed ID: 11240236
[TBL] [Abstract][Full Text] [Related]
6. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy.
Cheung R; Tucker SL; Lee AL; Dong L; Kamat A; Pisters L; Kuban DA
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):14-9. PubMed ID: 15629589
[TBL] [Abstract][Full Text] [Related]
7. A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition.
Critz FA
J Urol; 2002 Mar; 167(3):1310-3. PubMed ID: 11832720
[TBL] [Abstract][Full Text] [Related]
8. Definitions of biochemical failure in prostate cancer following radiation therapy.
Taylor JM; Griffith KA; Sandler HM
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1212-9. PubMed ID: 11483331
[TBL] [Abstract][Full Text] [Related]
9. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?
Kuban D; Thames H; Levy L; Horwitz E; Kupelian P; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):409-14. PubMed ID: 15667960
[TBL] [Abstract][Full Text] [Related]
10. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878
[TBL] [Abstract][Full Text] [Related]
11. A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria.
Gretzer MB; Trock BJ; Han M; Walsh PC
J Urol; 2002 Oct; 168(4 Pt 1):1419-22. PubMed ID: 12352408
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy.
Pickles T;
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1355-9. PubMed ID: 16406391
[TBL] [Abstract][Full Text] [Related]
13. Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1 ng/mL as endpoint.
Perez CA; Michalski JM; Lockett MA
Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1287-96. PubMed ID: 11286836
[TBL] [Abstract][Full Text] [Related]
14. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?
Nielsen ME; Makarov DV; Humphreys E; Mangold L; Partin AW; Walsh PC
Urology; 2008 Aug; 72(2):389-93; discussion 394-5. PubMed ID: 18279937
[TBL] [Abstract][Full Text] [Related]
15. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
16. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
Roach M; Hanks G; Thames H; Schellhammer P; Shipley WU; Sokol GH; Sandler H
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):965-74. PubMed ID: 16798415
[TBL] [Abstract][Full Text] [Related]
17. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
[TBL] [Abstract][Full Text] [Related]
18. [Biochemical recurrence criteria after radiotherapy (external beam, brachytherapy). Natural history of the disease after radiotherapy].
Villoslada CI; Olombrada MV; San Segundo CG
Arch Esp Urol; 2012; 65(1):12-20. PubMed ID: 22318174
[TBL] [Abstract][Full Text] [Related]
19. Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer.
Denham JW; Kumar M; Gleeson PS; Lamb DS; Joseph D; Atkinson C; Matthews J; Tai KH; Spry NA; Christie D; Turner S; Greer PB; D'Este C; Steigler A
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):404-11. PubMed ID: 19176272
[TBL] [Abstract][Full Text] [Related]
20. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.
Kuban DA; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Zietman AL
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):915-28. PubMed ID: 14575822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
